FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4243043443> ?p ?o ?g. }

• W4243043443 endingPage "123" @default.
• W4243043443 startingPage "101" @default.
• W4243043443 abstract "Everolimus (RAD001) is an oral protein kinase inhibitor of the mTOR (mammalian target of rapamycin) serine/threonine kinase signal transduction pathway. The mTOR pathway regulates cell growth, proliferation and survival, and is frequently deregulated in cancer.The EMA has approved Everolimus as Afinitor® for the treatment of hormone receptor-positive, HER2/neu-negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a nonsteroidal aromatase inhibitor, for the treatment of unresectable or metastatic, well- or moderately differentiated neuroendocrine tumors of pancreatic origin in adults with progressive disease, and for the treatment of unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) nonfunctional neuroendocrine tumors of gastrointestinal or lung origin in adults with progressive disease, and for the treatment of patients with advanced renal cell carcinoma, whose disease has progressed on or after treatment with VEGF-targeted therapy And as Votubia® for the treatment of adult patients with renal angiomyolipoma associated with tuberous sclerosis complex (TSC), who are at risk of complications (based on factors such as tumor size or presence of aneurysm, or presence of multiple or bilateral tumors) but who do not require immediate surgery, and for the treatment of patients with subependymal giant cell astrocytoma (SEGA) associated with TSC who require therapeutic intervention but are not amenable to surgery, and as an add-on treatment in patients from 2 years of age with seizures related to TSC that have not responded to other treatments ( https://www.novartis.com/news/media-releases/novartis-drug-votubiar-receives-eu-approval-treat-refractory-partial-onset ). The FDA has approved Everolimus as Afinitor® for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane, after the failure of treatment with letrozole or anastrozole, for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin (PNET) with unresectable, locally advanced or metastatic disease, for the treatment of adult patients with advanced RCC after failure of treatment with sunitinib or sorafenib, for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. for the treatment of adult and pediatric patients, 3 years of age or older, with SEGA associated with TSC who require therapeutic intervention but are not candidates for curative surgical resection. Everolimus shows promising clinical activity in additional indications. Multiple Phase II and Phase III trials of everolimus alone or in combination and will help to further elucidate the role of mTOR in oncology. For a review on everolimus as immunosuppressant, please consult other sources." @default.
• W4243043443 created "2022-05-12" @default.
• W4243043443 creator A5042854419 @default.
• W4243043443 date "2018-01-01" @default.
• W4243043443 modified "2023-10-09" @default.
• W4243043443 title "Everolimus" @default.
• W4243043443 cites W1861759122 @default.
• W4243043443 cites W1975317091 @default.
• W4243043443 cites W1979060986 @default.
• W4243043443 cites W1986262462 @default.
• W4243043443 cites W1988609792 @default.
• W4243043443 cites W1989779456 @default.
• W4243043443 cites W1996490009 @default.
• W4243043443 cites W1996837546 @default.
• W4243043443 cites W2013453542 @default.
• W4243043443 cites W2017018900 @default.
• W4243043443 cites W2017605860 @default.
• W4243043443 cites W2019874087 @default.
• W4243043443 cites W2019951496 @default.
• W4243043443 cites W2025344915 @default.
• W4243043443 cites W2027166833 @default.
• W4243043443 cites W2028549543 @default.
• W4243043443 cites W2029336551 @default.
• W4243043443 cites W2032870664 @default.
• W4243043443 cites W2035495486 @default.
• W4243043443 cites W2036950786 @default.
• W4243043443 cites W2040182003 @default.
• W4243043443 cites W2047257824 @default.
• W4243043443 cites W2047440678 @default.
• W4243043443 cites W2056111473 @default.
• W4243043443 cites W2059411043 @default.
• W4243043443 cites W2074642769 @default.
• W4243043443 cites W2076174029 @default.
• W4243043443 cites W2076379150 @default.
• W4243043443 cites W2088661762 @default.
• W4243043443 cites W2103808574 @default.
• W4243043443 cites W2105196235 @default.
• W4243043443 cites W2106885203 @default.
• W4243043443 cites W2112064092 @default.
• W4243043443 cites W2113505947 @default.
• W4243043443 cites W2115686439 @default.
• W4243043443 cites W2116542833 @default.
• W4243043443 cites W2118677643 @default.
• W4243043443 cites W2120661754 @default.
• W4243043443 cites W2127063807 @default.
• W4243043443 cites W2127931911 @default.
• W4243043443 cites W2128267006 @default.
• W4243043443 cites W2128965737 @default.
• W4243043443 cites W2134392974 @default.
• W4243043443 cites W2134749898 @default.
• W4243043443 cites W2135426730 @default.
• W4243043443 cites W2136212424 @default.
• W4243043443 cites W2138129102 @default.
• W4243043443 cites W2141161352 @default.
• W4243043443 cites W2146711059 @default.
• W4243043443 cites W2146778486 @default.
• W4243043443 cites W2148933046 @default.
• W4243043443 cites W2152289580 @default.
• W4243043443 cites W2152365295 @default.
• W4243043443 cites W2153061474 @default.
• W4243043443 cites W2153493705 @default.
• W4243043443 cites W2154515817 @default.
• W4243043443 cites W2159967578 @default.
• W4243043443 cites W2162242700 @default.
• W4243043443 cites W2164895949 @default.
• W4243043443 cites W2165901246 @default.
• W4243043443 cites W2166199281 @default.
• W4243043443 cites W2167188058 @default.
• W4243043443 cites W2169338340 @default.
• W4243043443 cites W2209368665 @default.
• W4243043443 cites W2298717328 @default.
• W4243043443 cites W2461990664 @default.
• W4243043443 cites W2471870867 @default.
• W4243043443 cites W2511912940 @default.
• W4243043443 cites W2519244199 @default.
• W4243043443 cites W2553007443 @default.
• W4243043443 cites W2565450772 @default.
• W4243043443 cites W2589722562 @default.
• W4243043443 cites W2609116961 @default.
• W4243043443 cites W3117975060 @default.
• W4243043443 doi "https://doi.org/10.1007/978-3-319-91442-8_8" @default.
• W4243043443 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30069763" @default.
• W4243043443 hasPublicationYear "2018" @default.
• W4243043443 type Work @default.
• W4243043443 citedByCount "60" @default.
• W4243043443 countsByYear W42430434432018 @default.
• W4243043443 countsByYear W42430434432019 @default.
• W4243043443 countsByYear W42430434432020 @default.
• W4243043443 countsByYear W42430434432021 @default.
• W4243043443 countsByYear W42430434432022 @default.
• W4243043443 countsByYear W42430434432023 @default.
• W4243043443 crossrefType "book-chapter" @default.
• W4243043443 hasAuthorship W4243043443A5042854419 @default.
• W4243043443 hasConcept C121608353 @default.
• W4243043443 hasConcept C126322002 @default.
• W4243043443 hasConcept C142724271 @default.
• W4243043443 hasConcept C143998085 @default.
• W4243043443 hasConcept C2775860665 @default.

• next